

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

**SACRX CORPORATION dba TRI STAR PHARMACY 2;
TOAN D. BUI, CHIEF EXECUTIVE OFFICER, 100% SHAREHOLDER,
DIRECTOR, SECRETARY AND TREASURER/CHIEF FINANCIAL
OFFICER**

Pharmacy Permit No. PHY 56125;

and

**HANH HONG THI TRAN,
Pharmacist License No. RPH 56990,**

Respondents.

Agency Case No. 7478

OAH No. 2024010222

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on September 20, 2024.

It is so ORDERED on August 21, 2024.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

By

A handwritten signature in black ink, appearing to read "Seung W. Oh". The signature is written in a cursive style with a large initial "S" and "O".

Seung W. Oh, Pharm.D.
Board President

1 ROB BONTA
Attorney General of California
2 ANDREW M. STEINHEIMER
Supervising Deputy Attorney General
3 JEFF STONE
Deputy Attorney General
4 State Bar No. 155190
1300 I Street, Suite 125
5 P.O. Box 944255
Sacramento, CA 94244-2550
6 Telephone: (916) 210-7726
Facsimile: (916) 327-8643
7 E-mail: Jeff.Stone@doj.ca.gov
Attorneys for Complainant
8

9
10 **BEFORE THE**
BOARD OF PHARMACY
11 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA
12
13
14

15 In the Matter of the Accusation Against:

16 **SACRX CORPORATION dba TRI STAR**
PHARMACY 2; TOAN D. BUI, CHIEF
17 **EXECUTIVE OFFICER, 100%**
SHAREHOLDER, DIRECTOR,
18 **SECRETARY AND TREASURER/CHIEF**
FINANCIAL OFFICER
19 6540 Stockton Blvd., #3B
Sacramento, CA 95823

20 **Pharmacy Permit No. PHY 56125**

21 **HANH HONG THI TRAN**
22 2795 Aberdeen Ln.
El Dorado Hills, CA 95762

23 **Pharmacist License No. RPH 56990**

24 Respondents.
25

Case No. 7478

OAH No. 2024010222

STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER AS TO HANH
HONG THI TRAN ONLY

26
27 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
28 entitled proceedings that the following matters are true:

1 **PARTIES**

2 1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy
3 (Board). She brought this action solely in her official capacity and is represented in this matter by
4 Rob Bonta, Attorney General of the State of California, by Jeff Stone, Deputy Attorney General.

5 2. Respondent HANH HONG THI TRAN (Respondent) is represented in this
6 proceeding by attorney Ivan Petrzelka, P.O. Box 552, Red Bluff, CA 96080.

7 3. On or about May 4, 2005, the Board issued Pharmacist License number RPH 56990
8 to Respondent Tran. Respondent’s Pharmacist License was in full force and effect at all times
9 relevant herein and will expire on July 31, 2024, unless renewed.

10 **JURISDICTION**

11 4. Accusation No. 7478 was filed before the Board, and is currently pending against
12 Respondent. The Accusation and all other statutorily required documents were properly served
13 on Respondent on July 28, 2023. Respondent timely filed her Notice of Defense contesting the
14 Accusation.

15 5. A copy of Accusation No. 7478 is attached as exhibit A and incorporated herein by
16 reference.

17 **ADVISEMENT AND WAIVERS**

18 6. Respondent has carefully read, fully discussed with counsel, and understands the
19 charges and allegations in Accusation No. 7478. Respondent has also carefully read, fully
20 discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary
21 Order.

22 7. Respondent is fully aware of her legal rights in this matter, including the right to a
23 hearing on the charges and allegations in the Accusation; the right to confront and cross-examine
24 the witnesses against them; the right to present evidence and to testify on her own behalf; the
25 right to the issuance of subpoenas to compel the attendance of witnesses and the production of
26 documents; the right to reconsideration and court review of an adverse decision; and all other
27 rights accorded by the California Administrative Procedure Act and other applicable laws.

28 ///

1 Failure to timely report such occurrence shall be considered a violation of probation.

2 **2. Report to the Board**

3 Respondent shall report to the Board quarterly, on a schedule as directed by the Board or its
4 designee. The report shall be made either in person or in writing, as directed. Among other
5 requirements, respondent shall state in each report under penalty of perjury whether there has
6 been compliance with all the terms and conditions of probation.

7 Failure to submit timely reports in a form as directed shall be considered a violation of
8 probation. Any period(s) of delinquency in submission of reports as directed may be added to the
9 total period of probation. Moreover, if the final probation report is not made as directed,
10 probation shall be automatically extended until such time as the final report is made and accepted
11 by the Board.

12 **3. Interview with the Board**

13 Upon receipt of reasonable prior notice, respondent shall appear in person for interviews
14 with the Board or its designee, at such intervals and locations as are determined by the Board or
15 its designee. Failure to appear for any scheduled interview without prior notification to Board
16 staff, or failure to appear for two (2) or more scheduled interviews with the Board or its designee
17 during the period of probation, shall be considered a violation of probation.

18 **4. Cooperate with Board Staff**

19 Respondent shall timely cooperate with the Board's inspection program and with the
20 Board's monitoring and investigation of respondent's compliance with the terms and conditions of
21 her probation, including but not limited to: timely responses to requests for information by Board
22 staff; timely compliance with directives from Board staff regarding requirements of any term or
23 condition of probation; and timely completion of documentation pertaining to a term or condition
24 of probation. Failure to timely cooperate shall be considered a violation of probation.

25 **5. Continuing Education**

26 Respondent shall provide evidence of efforts to maintain skill and knowledge as a
27 pharmacist as directed by the Board or its designee.

28 ///

1 **6. Reporting of Employment and Notice to Employers**

2 During the period of probation, respondent shall notify all present and prospective
3 employers of the decision in case number 7478 and the terms, conditions and restrictions imposed
4 on respondent by the decision, as follows:

5 Within thirty (30) days of the effective date of this decision, and within ten (10) days of
6 undertaking any new employment, respondent shall report to the Board in writing the name,
7 physical address, and mailing address of each of her employer(s), and the name(s) and telephone
8 number(s) of all of her direct supervisor(s), as well as any pharmacist(s)-in-charge, designated
9 representative(s)-in-charge, responsible manager, or other compliance supervisor(s) and the work
10 schedule, if known. Respondent shall also include the reason(s) for leaving the prior
11 employment. Respondent shall sign and return to the Board a written consent authorizing the
12 Board or its designee to communicate with all of respondent's employer(s) and supervisor(s), and
13 authorizing those employer(s) or supervisor(s) to communicate with the Board or its designee,
14 concerning respondent's work status, performance, and monitoring. Failure to comply with the
15 requirements or deadlines of this condition shall be considered a violation of probation.

16 Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of
17 respondent undertaking any new employment, respondent shall cause (a) her direct supervisor, (b)
18 her pharmacist-in-charge, designated representative-in-charge, responsible manager, or other
19 compliance supervisor, and (c) the owner or owner representative of her employer, to report to the
20 Board in writing acknowledging that the listed individual(s) has/have read the decision in case
21 number 7478, and terms and conditions imposed thereby. If one person serves in more than one
22 role described in (a), (b), or (c), the acknowledgment shall so state. It shall be the respondent's
23 responsibility to ensure that these acknowledgment(s) are timely submitted to the Board. In the
24 event of a change in the person(s) serving the role(s) described in (a), (b), or (c) during the term
25 of probation, respondent shall cause the person(s) taking over the role(s) to report to the Board in
26 writing within fifteen (15) days of the change acknowledging that he or she has read the decision
27 in case number 7478, and the terms and conditions imposed thereby.

28 ///

1 If respondent works for or is employed by or through an employment service, respondent
2 must notify the person(s) described in (a), (b), and (c) above at every entity licensed by the Board
3 of the decision in case number 7478, and the terms and conditions imposed thereby in advance of
4 respondent commencing work at such licensed entity. A record of this notification must be
5 provided to the Board upon request.

6 Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen
7 (15) days of respondent undertaking any new employment by or through an employment service,
8 respondent shall cause the person(s) described in (a), (b), and (c) above at the employment service
9 to report to the Board in writing acknowledging that he or she has read the decision in case
10 number, and the terms and conditions imposed thereby. It shall be respondent's responsibility to
11 ensure that these acknowledgment(s) are timely submitted to the Board.

12 Failure to timely notify present or prospective employer(s) or failure to cause the identified
13 person(s) with that/those employer(s) to submit timely written acknowledgments to the Board
14 shall be considered a violation of probation.

15 "Employment" within the meaning of this provision includes any full-time, part-time,
16 temporary, relief, or employment/management service position as a pharmacist, or any position
17 for which a pharmacist is a requirement or criterion for employment, whether the respondent is an
18 employee, independent contractor or volunteer.

19 **7. Notification of Change(s) in Name, Address(es), or Phone Number(s)**

20 Respondent shall further notify the Board in writing within ten (10) days of any change in
21 name, residence address, mailing address, e-mail address or phone number.

22 Failure to timely notify the Board of any change in employer, name, address, or phone
23 number shall be considered a violation of probation.

24 **8. Restrictions on Supervision and Oversight of Licensed Facilities**

25 During the period of probation, respondent shall not supervise any intern pharmacist, be the
26 pharmacist-in-charge, designated representative-in-charge, responsible manager or other
27 compliance supervisor of any entity licensed by the Board, nor serve as a consultant. Assumption
28 of any such unauthorized supervision responsibilities shall be considered a violation of probation.

1 **9. Reimbursement of Board Costs**

2 As a condition precedent to successful completion of probation, respondent shall pay to the
3 Board its costs of investigation and prosecution in the amount of \$15,000.00. Respondent is
4 jointly and severally liable for these costs with Respondent SacRx Corporation dba Tri Star
5 Pharmacy 2, with Toan D. Bui Chief Executive Officer, 100% Shareholder, Director, Secretary,
6 and Treasurer/Chief Financial Officer. Failure to pay costs by the deadline(s) as directed shall be
7 considered a violation of probation. Respondent shall be permitted to pay these costs in a
8 payment plan approved by the Board or its designee, so long as full payment is completed no later
9 than one (1) year prior to the end date of probation.

10 **10. Probation Monitoring Costs**

11 Respondent shall pay any costs associated with probation monitoring as determined by the
12 Board each and every year of probation. Such costs shall be payable to the Board on a schedule
13 as directed by the Board or its designee. Failure to pay such costs by the deadline(s) as directed
14 shall be considered a violation of probation.

15 **11. Status of License**

16 Respondent shall, at all times while on probation, maintain an active, current Pharmacist
17 License with the Board, including any period during which suspension or probation is tolled.
18 Failure to maintain an active, current Pharmacist License shall be considered a violation of
19 probation.

20 If respondent's Pharmacist License expires or is cancelled by operation of law or otherwise
21 at any time during the period of probation, including any extensions thereof due to tolling or
22 otherwise, upon renewal or reapplication respondent's license shall be subject to all terms and
23 conditions of this probation not previously satisfied.

24 **12. License Surrender While on Probation/Suspension**

25 Following the effective date of this decision, should respondent cease practice due to
26 retirement or health, or be otherwise unable to satisfy the terms and conditions of probation,
27 respondent may relinquish her pharmacist license, including any indicia of licensure issued by the
28 Board, along with a request to surrender the license. The Board or its designee shall have the

1 discretion whether to accept the surrender or take any other action it deems appropriate and
2 reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be
3 subject to the terms and conditions of probation. This surrender constitutes a record of discipline
4 and shall become a part of the respondent's license history with the Board.

5 Upon acceptance of the surrender, respondent shall relinquish her pocket and/or wall
6 license, including any indicia of licensure not previously provided to the Board within ten (10)
7 days of notification by the Board that the surrender is accepted if not already provided.
8 Respondent may not reapply for any license from the Board for three (3) years from the effective
9 date of the surrender. Respondent shall meet all requirements applicable to the license sought as
10 of the date the application for that license is submitted to the Board, including any outstanding
11 costs.

12 **13. Practice Requirement – Extension of Probation**

13 Except during periods of suspension, respondent shall, at all times while on probation, be
14 employed as a pharmacist in California for a minimum of eighty (80) hours per calendar month.
15 Any month during which this minimum is not met shall extend the period of probation by one
16 month. During any such period of insufficient employment, respondent must nonetheless comply
17 with all terms and conditions of probation, unless respondent receives a waiver in writing from
18 the Board or its designee.

19 If respondent does not practice as a pharmacist in California for the minimum number of
20 hours in any calendar month, for any reason (including vacation), respondent shall notify the
21 Board in writing within ten (10) days of the conclusion of that calendar month. This notification
22 shall include at least: the date(s), location(s), and hours of last practice; the reason(s) for the
23 interruption or reduction in practice; and the anticipated date(s) on which respondent will resume
24 practice at the required level. Respondent shall further notify the Board in writing within ten (10)
25 days following the next calendar month during which respondent practices as a pharmacist in
26 California for the minimum of hours. Any failure to timely provide such notification(s) shall be
27 considered a violation of probation.

28 ///

1 It is a violation of probation for respondent's probation to be extended pursuant to the
2 provisions of this condition for a total period, counting consecutive and non-consecutive months,
3 exceeding thirty-six (36) months. The Board or its designee may post a notice of the extended
4 probation period on its website.

5 **13. Violation of Probation**

6 If respondent has not complied with any term or condition of probation, the Board shall
7 have continuing jurisdiction over respondent, and the Board shall provide notice to respondent
8 that probation shall automatically be extended, until all terms and conditions have been satisfied
9 or the Board has taken other action as deemed appropriate to treat the failure to comply as a
10 violation of probation, to terminate probation, and to impose the penalty that was stayed. The
11 Board or its designee may post a notice of the extended probation period on its website.

12 If respondent violates probation in any respect, the Board, after giving respondent notice
13 and an opportunity to be heard, may revoke probation and carry out the disciplinary order that
14 was stayed. If a petition to revoke probation or an accusation is filed against respondent during
15 probation, or the preparation of an accusation or petition to revoke probation is requested from
16 the Office of the Attorney General, the Board shall have continuing jurisdiction and the period of
17 probation shall be automatically extended until the petition to revoke probation or accusation is
18 heard and decided, and the charges and allegations in Accusation 7478 shall be deemed true and
19 correct.

20 **14. Completion of Probation**

21 Upon written notice by the Board or its designee indicating successful completion of
22 probation, respondent's license will be fully restored.

23 **15. Remedial Education**

24 Within sixty (60) days of the effective date of this decision, respondent shall submit to the
25 Board or its designee, for prior approval, an appropriate program of remedial education related to
26 the causes for discipline in Accusation No. 7478, and must pertain to pharmacy law and
27 operations. The program of remedial education shall consist of at least six (6) hours per year of
28 probation, at respondent's own expense, and fifty percent (50%) of the program for remedial

1 education shall be in-person or live webinar. All remedial education shall be in addition to, and
2 shall not be credited toward, continuing education (CE) courses used for license renewal purposes
3 for pharmacists.

4 Failure to timely submit for approval or complete the approved remedial education shall be
5 considered a violation of probation. The period of probation will be automatically extended until
6 such remedial education is successfully completed and written proof, in a form acceptable to the
7 Board, is provided to the Board or its designee. Following the completion of each course, the
8 Board or its designee may require the respondent, at her own expense, to take an approved
9 examination to test the respondent's knowledge of the course. If respondent does not achieve a
10 passing score on the examination that course shall not count towards satisfaction of this term.
11 Respondent shall take another course approved by the Board in the same subject area.

12 **16. Ethics Course**

13 Within sixty (60) calendar days of the effective date of this decision, respondent shall enroll
14 in a course in ethics, at respondent's expense, approved in advance by the Board or its designee
15 that complies with Title 16 California Code of Regulations section 1773.5. Within this time-
16 frame, on submission by respondent and approval by the Board or its designee of acceptable
17 documentation, credit will be given to respondent for a course that was completed by respondent
18 within two (2) years prior to the effective date of this decision.

19 For a course in ethics taken during the term of probation, respondent shall provide proof of
20 enrollment upon request. Within five (5) days of completion of a course in ethics during the
21 probation term, respondent shall submit a copy of the certificate of completion to the Board or its
22 designee. Failure to timely enroll in an approved ethics course, to initiate the course during the
23 first year of probation, to successfully complete it before the end of the second year of probation,
24 or to timely submit proof of completion to the Board or its designee, shall be considered a
25 violation of probation.

26 **17. No Ownership or Management of Licensed Premises**

27 Respondent shall not own, have any legal or beneficial interest in, nor serve as a manager,
28 administrator, member, officer, director, trustee, associate, or partner of any business, firm,

1 partnership, or corporation currently or hereinafter licensed by the Board. Respondent shall sell
2 or transfer any legal or beneficial interest in any entity licensed by the Board within ninety (90)
3 days following the effective date of this decision and shall immediately thereafter provide written
4 proof thereof to the Board. Failure to timely divest any legal or beneficial interest(s) or provide
5 documentation thereof shall be considered a violation of probation.

6 **ACCEPTANCE**

7 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully
8 discussed it with my attorney, Ivan Petrzelka. I understand the stipulation and the effect it will
9 have on my Pharmacist License. I enter into this Stipulated Settlement and Disciplinary Order
10 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
11 Board of Pharmacy.

12
13 DATED: _____

14 HANH HONG THI TRAN
15 *Respondent*

16
17 I have read and fully discussed with Respondent Hanh Hong Thi Tran the terms and
18 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.
19 I approve its form and content.

20
21 DATED: _____

22 IVAN PETRZELKA
23 *Attorney for Respondent*

1 partnership, or corporation currently or hereinafter licensed by the Board. Respondent shall sell
2 or transfer any legal or beneficial interest in any entity licensed by the Board within ninety (90)
3 days following the effective date of this decision and shall immediately thereafter provide written
4 proof thereof to the Board. Failure to timely divest any legal or beneficial interest(s) or provide
5 documentation thereof shall be considered a violation of probation.

6 ACCEPTANCE


7 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully
8 discussed it with my attorney, Ivan Petrzelka. I understand the stipulation and the effect it will
9 have on my Pharmacist License. I enter into this Stipulated Settlement and Disciplinary Order
10 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
11 Board of Pharmacy.

12
13 DATED: 6-26-2024


14 HANH HONG THI TRAN
15 Respondent

16
17 I have read and fully discussed with Respondent Hanh Hong Thi Tran the terms and
18 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.
19 I approve its form and content.

20 DATED: June 26, 2024


21 IVAN PETRZELKA
22 Attorney for Respondent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Board of Pharmacy.

DATED: _____

Respectfully submitted,
ROB BONTA
Attorney General of California
ANDREW M. STEINHEIMER
Supervising Deputy Attorney General

JEFF STONE
Deputy Attorney General
Attorneys for Complainant

SA2023302721
Tri Star Stipulated Settlement - PIC.docx

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Board of Pharmacy.

DATED: 6/26/24

Respectfully submitted,

ROB BONTA
Attorney General of California
ANDREW M. STEINHEIMER
Supervising Deputy Attorney General



JEFF STONE
Deputy Attorney General
Attorneys for Complainant

SA2023302721
Tri Star Stipulated Settlement - PIC.docx

Exhibit A

Accusation No. 7478

1 ROB BONTA
Attorney General of California
2 ANDREW M. STEINHEIMER
Supervising Deputy Attorney General
3 JEFF STONE
Deputy Attorney General
4 State Bar No. 155190
1300 I Street, Suite 125
5 P.O. Box 944255
Sacramento, CA 94244-2550
6 Telephone: (916) 210-7726
Facsimile: (916) 327-8643
7 E-mail: Jeff.Stone@doj.ca.gov
Attorneys for Complainant
8

9 **BEFORE THE**
10 **BOARD OF PHARMACY**
11 **DEPARTMENT OF CONSUMER AFFAIRS**
12 **STATE OF CALIFORNIA**

13 In the Matter of the Accusation Against:

Case No. 7478

14 **SACRX CORPORATION dba TRI STAR**
15 **PHARMACY 2; TOAN D. BUI, CHIEF**
16 **EXECUTIVE OFFICER, 100%**
17 **SHAREHOLDER, DIRECTOR,**
18 **SECRETARY AND TREASURER/CHIEF**
19 **FINANCIAL OFFICER**
6540 Stockton Blvd., #3B
Sacramento, CA 95823

OAH No. 2023040481

ACCUSATION

Pharmacy Permit No. PHY 56125

20 **HANH HONG THI TRAN**
21 2795 Aberdeen Ln.
El Dorado Hills, CA 95762

22 **Pharmacist License No. RPH 56990**

23 Respondents.

24 **PARTIES**

25
26 1. Anne Sodergren (“Complainant”) brings this Accusation solely in her official
27 capacity as the Executive Officer of the Board of Pharmacy (“Board”), Department of Consumer
28 Affairs.

1 (7) Compliance with laws and regulations governing the practice of pharmacy.

2 . . .

3 (d) The board may initiate disciplinary proceedings to revoke or suspend any
4 probationary certificate of licensure for any violation of the terms and conditions of
probation. Upon satisfactory completion of probation, the board shall convert the
probationary certificate to a regular certificate, free of conditions.

5 (e) The proceedings under this article shall be conducted in accordance with
6 Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the
7 Government Code, and the board shall have all the powers granted therein. The
action shall be final, except that the propriety of the action is subject to review by the
superior court pursuant to Section 1094.5 of the Code of Civil Procedure.

8 8. Code section 4300.1 states:

9 The expiration, cancellation, forfeiture, or suspension of a board issued license by
10 operation of law or by order or decision of the board or a court of law, the placement
of a license on a retired status, or the voluntary surrender of a license by a licensee
11 shall not deprive the board of jurisdiction to commence or proceed with any
investigation of, or action or disciplinary proceeding against, the licensee or to render
12 a decision suspending or revoking the license.

13 9. Code section 4307, subdivision (a) states:

14 (a) Any person who has been denied a license or whose license has been revoked or
15 is under suspension, or who has failed to renew his or her license while it was under
suspension, or who has been a manager, administrator, owner, member, officer,
16 director, associate, or partner of any partnership, corporation, firm or association
whose application for a license has been denied or revoked, is under suspension or
17 has been placed on probation, and while acting as the manager, administrator owner,
member, officer, director, associate, or partner had knowledge of or knowingly
18 participated in any conduct for which the license was denied, revoked, suspended or
placed on probation, shall be prohibited from serving as a manager, administrator,
owner, member, officer, director, associate, or partner of a licensee as follows:

19 (1) Where a probationary license is issued or where an existing license is placed
20 on probation, this prohibition shall remain in effect for a period not to exceed five
years.

21 (2) Where the license is denied or revoked, the prohibition shall continue until
22 the license is issued or reinstated.

23 **STATUTORY PROVISIONS**

24 10. Code section 4022 states:

25 Dangerous drug or dangerous device means any drug or device unsafe for
self-use in humans or animals, and includes the following:

26 (a) Any drug that bears the legend: Caution: federal law prohibits dispensing without
27 prescription, Rx only, or words of similar import.

28 (b) Any device that bears the statement: Caution: federal law restricts this device to
sale by or on the order of a _____, Rx only, or words of similar import, the

1 blank to be filled in with the designation of the practitioner licensed to use or order
2 use of the device.

3 (c) Any other drug or device that by federal or state law can be lawfully dispensed
4 only on prescription or furnished pursuant to Section 4006.

5 11. Code section 4081 provides, in pertinent part:

6 (a) All records of manufacture and of sale, acquisition, or disposition of dangerous
7 drugs or dangerous devices shall be at all times during business hours open to
8 inspection by authorized officers of the law, and shall be preserved for at least three
9 years from the date of making. A current inventory shall be kept by every
10 manufacturer, wholesaler, pharmacy, veterinary food-animal drug retailer, physician,
11 dentist, podiatrist, veterinarian, laboratory, clinic, hospital, institution, or
12 establishment holding a currently valid and unrevoked certificate, license, permit,
13 registration, or exemption under Division 2 (commencing with Section 1200) of the
14 Health and Safety Code or under Part 4 (commencing with Section 16000) of
15 Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous
16 drugs or dangerous devices.

17 (b) The owner, officer, and partner of any pharmacy, wholesaler, or veterinary
18 food-animal drug retailer shall be jointly responsible, with the pharmacist-in-charge
19 or representative-in-charge, for maintaining the records and inventory described in
20 this section.

21 ...

22 (d) Pharmacies that dispense nonprescription diabetes test devices pursuant to
23 prescriptions shall retain records of acquisition and sale of those nonprescription
24 diabetes test devices for at least three years from the date of making. The records
25 shall be at all times during business hours open to inspection by authorized officers of
26 the law.

27 ...

28 12. Code section 4115 provides, in pertinent part:

(a) A pharmacy technician may perform packaging, manipulative, repetitive, or other
nondiscretionary tasks only while assisting, and while under the direct supervision
and control of, a pharmacist. The pharmacist shall be responsible for the duties
performed under his or her supervision by a technician.

...

(e) A person shall not act as a pharmacy technician without first being licensed by the

...

13. Code section 4301 provides, in pertinent part:

The board shall take action against any holder of a license who is guilty of
unprofessional conduct or whose license has been issued by mistake. Unprofessional
conduct shall include, but is not limited to, any of the following:

1 ...
2 (f) The commission of any act involving moral turpitude, dishonesty, fraud, deceit, or
3 otherwise, and whether the act is a felony or misdemeanor or not.

4 ...
5 (j) The violation of any of the statutes of this state, of any other state, or of the
6 United States regulating controlled substances and dangerous drugs.

7 ...
8 (o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting
9 the violation of or conspiring to violate any provision or term of this chapter or of the
10 applicable federal and state laws and regulations governing pharmacy, including
11 regulations established by the board or by any other state or federal regulatory
12 agency.

13 ...
14 **REGULATORY PROVISIONS**

15 14. California Code of Regulations, title 16, (CCR) section 1707.2 provides, in pertinent
16 part:

17 ...
18 (b)(1) When the patient or patient's agent is not present (including, but not limited to,
19 a prescription drug that was shipped by mail or delivery), a pharmacy shall ensure
20 that:

21 (A) the patient receives written notice of his or her right to request consultation;

22 (B) the patient receives written notice of the hours of availability and the telephone
23 number from which the patient may obtain oral consultation from a pharmacist who
24 has ready access to the patient's record; and

25 (C) a pharmacist shall be available

26 (i) to speak to the patient or patient's agent during any regular hours of
27 operation, within an average of ten (10) minutes or less, unless a return call is
28 scheduled to occur within one business hour,

(ii) for no less than six days per week, and (iii) for a minimum of 40 hours
per week.

(2) A pharmacist is not required by this subsection to provide oral consultation to an
inpatient of a health care facility licensed pursuant to section 1250 of the Health and
Safety Code, or to an inmate of an adult correctional facility or a juvenile detention
facility, except upon the patient's discharge. A pharmacist is not obligated to consult
about discharge medications if a health facility licensed pursuant to subdivision (a) or
(b) of Health and Safety Code Section 1250 has implemented a written policy about
discharge medications which meets the requirements of Business and Professions
Code Section 4074.

...

15. CCR section 1714 provides, in pertinent part:

(b) Each pharmacy licensed by the board shall maintain its facilities, space, fixtures, and equipment so that drugs are safely and properly prepared, maintained, secured and distributed. The pharmacy shall be of sufficient size and unobstructed area to accommodate the safe practice of pharmacy.

(c) The pharmacy and fixtures and equipment shall be maintained in a clean and orderly condition. The pharmacy shall be dry, well-ventilated, free from rodents and insects, and properly lighted. The pharmacy shall be equipped with a sink with hot and cold running water for pharmaceutical purposes.

(d) Each pharmacist while on duty shall be responsible for the security of the prescription department, including provisions for effective control against theft or diversion of dangerous drugs and devices, and records for such drugs and devices. Possession of a key to the pharmacy where dangerous drugs and controlled substances are stored shall be restricted to a pharmacist.

(e) The pharmacy owner, the building owner or manager, or a family member of a pharmacist

...

16. CCR section 1715.65 provides, in pertinent part:

(a) Every pharmacy, and every clinic licensed under sections 4180 or 4190 of the Business and Professions Code, shall perform periodic inventory activities and prepare inventory reconciliation reports to detect and prevent the loss of federal controlled substances. Except as provided in subdivisions (f) and (g), inventory reconciliation reports shall be prepared on the following ongoing basis:

(1) For federal Schedule II controlled substances, at least once every three months.

(2) For products containing the following substances in the following strengths per tablet, capsule, other unit, or specified volume, at least once every 12 months:

(A) Alprazolam, 1 milligram/unit.

(B) Alprazolam, 2 milligrams/unit.

(C) Tramadol, 50 milligrams/unit.

(D) Promethazine/codeine, 6.25 milligrams of promethazine and 10 milligrams of codeine per 5 milliliters of product.

(3)

(A) For any controlled substance not covered by paragraph (1) or (2), an inventory reconciliation report shall be prepared for identified controlled substances lost no later than three months after discovery of the reportable loss of that controlled substance. This report shall be completed if the loss is discovered either by the inventory activities required by subparagraph (B), or in any other manner. The report

1 shall cover the period from the last physical count of that controlled substance before
2 the loss was discovered through the date of discovery. At a minimum, a reportable
3 loss is as specified in section 1715.6, or any pattern(s) of loss(es) identified by the
4 pharmacist in charge, as defined by the pharmacy's policies and procedures. A
5 reportable loss shall require an inventory reconciliation report for each pattern of loss
6 identified.

7 (B) Inventory activities for each controlled substance not covered by
8 paragraph (1) or (2) shall be performed at least once every two years from the
9 performance of the last inventory activities. For purposes of this section, "inventory
10 activities" means inventory and all other functions sufficient to identify loss of
11 controlled substances. The functions sufficient to identify loss outside of the
12 inventory reconciliation process shall be identified within the pharmacy's policies and
13 procedures.

14 (b) The pharmacist-in-charge of a pharmacy or consulting pharmacist for a clinic
15 shall review all inventory activities performed and inventory reconciliation reports
16 prepared pursuant to this section, and establish and maintain secure methods to
17 prevent losses of federal controlled substances. Written policies and procedures shall
18 be developed for performing the inventory activities and preparing the inventory
19 reconciliation reports required by this section.

20 (c) An inventory reconciliation report prepared pursuant to this section shall include
21 all of the following:

22 (1) A physical count, not an estimate, of all quantities of each federal controlled
23 substance covered by the report that the pharmacy or clinic has in inventory, except
24 as provided in subdivision (h). The biennial inventory of controlled substances
25 required by federal law may serve as one of the mandated inventories under this
26 section in the year where the federal biennial inventory is performed, provided the
27 biennial inventory was taken no more than three months from the last inventory
28 required by this section. An individual who performs the inventory required by this
paragraph shall sign and date the inventory or the report in which it is included as
provided in subdivision (e)(1);

(2) A review of all acquisitions and dispositions of each federal controlled substance
covered by the report since the last inventory reconciliation report covering that
controlled substance;

(3) A comparison of (1) and (2) to determine if there are any variances;

(4) Identification of all records used to compile the report, which shall be
maintained in the pharmacy or clinic pursuant to subdivision (e)(2);

(5) Identification of each individual involved in preparing the report; and

(6) Possible causes of overages.

(d) A pharmacy or clinic shall report in writing identified losses and known causes to
the board within 30 days of discovery unless the cause of the loss is theft, diversion,
or self-use in which case the report shall be made within 14 days of discovery. If the
pharmacy or clinic is unable to identify the cause of the loss, further investigation
shall be undertaken to identify the cause and actions necessary to prevent additional
losses of federal controlled substances.

(e)

1 (1) An inventory reconciliation report shall be dated and signed by the pharmacist-
2 in-charge or professional director (if a clinic), in addition to any signature required by
3 subdivision (c)(1). An individual may use a digital or electronic signature or
4 biometric identifier in lieu of a physical signature under this section if, in addition, the
5 individual physically signs a printed statement confirming the accuracy of the
6 inventory or report. The signature shall be dated, and the signed and dated statement
7 shall be retained on file pursuant to paragraph (2).

8 (2) The report, and all records used to compile the report, shall be readily retrievable
9 in the pharmacy or clinic for three years.

10 (f) A new pharmacist-in-charge of a pharmacy shall complete an inventory
11 reconciliation report for all federal controlled substances described in paragraphs (1)
12 and (2) of subdivision (a) within 30 days of becoming pharmacist-in-charge.
13 Whenever possible, an outgoing pharmacist-in-charge should also complete an
14 inventory reconciliation report for those controlled substances.

15 (g) Notwithstanding the periodic reporting requirements specified in paragraphs (1)
16 and (2) of subdivision (a), inpatient hospital pharmacies shall prepare an inventory
17 reconciliation report or reports covering the federal controlled substances described in
18 paragraphs (1) and (2) of subdivision (a) on a quarterly basis. The report or reports
19 shall include controlled substances stored within the pharmacy, within each pharmacy
20 satellite location, and within each drug storage area in the hospital under the
21 pharmacy's control.

22 (h) If an inpatient hospital pharmacy or licensed correctional pharmacy uses an
23 automated drug delivery system (ADDS), inventory in the ADDS may be accounted
24 for under subdivision (c)(1) using means other than a physical count.

25 ...

26 17. CCR section 1718 provides, in pertinent part:

27 "Current Inventory" as used in Sections 4081 and 4332 of the Business and
28 Professions Code shall be considered to include complete accountability for all
dangerous drugs handled by every licensee enumerated in Sections 4081 and 4332.

The controlled substances inventories required by Title 21, CFR, Section 1304 shall
be available for inspection upon request for at least 3 years after the date of the
inventory.

...

COST RECOVERY

18. Code section 125.3 provides, in pertinent part, that the Board may request the
administrative law judge to direct a licentiate found to have committed a violation or violations of
the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
enforcement of the case, with failure of the licentiate to comply subjecting the license to not being
renewed or reinstated. If a case settles, recovery of investigation and enforcement costs may be
included in a stipulated settlement.

- 1 • allowing an unlicensed pharmacy clerk to have possession and use of a
- 2 pharmacy key and open the pharmacy;
- 3 • failing to keep the premises in a clean and orderly condition by, among other
- 4 things, allowing a leaking and moldy ceiling in a medication prepackaging area,
- 5 and;
- 6 • preparing and delivering prescriptions for delivery that did not have notice of
- 7 right to consultation or medication guides.

8 22. More particularly, on June 7, 2022, Inspector S.M. noted prescriptions in the will-call
9 area that had been billed to patients' insurance plans for nearly one month, which had not been
10 picked up by the patients. As an example, a bag containing approximately 12 prescriptions for
11 patient TN had been processed and billed to the insurance plan on May 17, 2022 but remained at
12 the pharmacy on June 7, 2022.

13 23. On June 7, 2022, Inspector S.M. observed Mr. Bui, an unlicensed employee of
14 Respondent Tri Star, using a pharmacy key kept on his keychain to open the pharmacy door;
15 which conduct was evidenced on other occasions in video provided by the complaining
16 employee.

17 24. On June 7, 2022, Inspector S.M. also observed prescription documents and wholesale
18 invoices stored in cardboard boxes in the waiting area outside of the pharmacy. The boxes were
19 only taped closed and were not locked in a secure area.

20 25. On June 7, 2022, and again on October 31, 2022, Inspector S.M. also observed that
21 Respondent Tri Star was not in a clean and orderly condition. There were food
22 items, as well as cooking devices including a microwave oven, toaster oven, and a coffee
23 machine, in and around the medication filling area. Additionally, a back room used for
24 prepackaging and storing medications had moldy ceiling tiles and water marks running down the
25 wall.

26 26. On June 7, 2022, Inspector S.M. also observed that Respondents did not maintain
27 complete temperature logs documenting the refrigerator and freezer temperatures. While
28 refrigerator and freezer temperatures were written manually on a paper log taped to the

1 refrigerator, there were no temperatures documented to ensure proper medication storage since
2 May 27, 2022.

3 27. On June 7, 2022, Inspector S.M. observed that Respondents did not complete the
4 controlled substance reconciliation report on a quarterly basis. Respondents did not include all
5 required items including acquisition and disposition counts to determine variances, identification
6 of records used to compile the report, and causes of any variances.

7 28. On June 7, 2022, Inspector S.M. observed that Respondents did not provide a notice
8 of the right to consultation for all prescriptions packaged for delivery and did not provide
9 medication guides when necessary.

10 29. On or about June 20, August 11, and August 26, 2022 the Board received follow-up
11 emails from the complaining employee, including documentation, photographs and videos
12 relating to Respondents' violations of pharmacy law. On or about September 27, 2022, Inspector
13 S.M. spoke by telephone with the complaining employee regarding the complaining employees'
14 observations and reports of Respondents' violations of pharmacy law. On or about October 3,
15 2022, Inspector S.M. received another email from the complaining employee stated, among other
16 things, that medications were being taken home by employees for prepackaging, and were being
17 prepackaged by unlicensed personnel (including an unlicensed employee, Mr. Bui).

18 30. On or about December 1, 2022, Inspector S.M. sent emails to drug wholesalers
19 McKesson, Amerisource Bergen and API requesting purchase history records for drugs purchased
20 by Respondent Tri Star from January 1, 2020 to October 31, 2022. Between approximately
21 December 5, 2022 and December 29, 2022, Inspector Mullen received the purchase history
22 records from the wholesalers showing all purchases of, among other things, True Metrix blood
23 glucose meters (a dangerous drugs/device pursuant to Business and Professions Code section
24 4402) and COVID home testing kits purchased by Tri Star from January 1, 2020 to October 31,
25 2022.

26 31. On January 12, 2023, Inspector S.M. visited Respondent Tri Star and, among other
27 things, spoke with Respondent Tran about individuals working at Respondent Tri Star depicted in
28 photographs taken from videos provided by the complaining employee. Three of the photographs

1 depicted different individuals working at the counting machine used for prepackaging
2 prescriptions - a task for which a Board license is required. Respondent Tran identified one of the
3 individuals as her father Tuan Tran (unlicensed by the Board) and said he was “fixing the
4 machine”, another as her mother Thi Truong (unlicensed by the Board) and said she was
5 “cleaning the machine”, and the third as Dieu Bui, Mr. Bui’s sister (unlicensed by the Board) and
6 said she was also “cleaning the machine”. Another photograph appearing to show an individual
7 filling prescriptions was identified by Respondent Tran as clerk Vida Lam (unlicensed by the
8 Board) and stated she was “putting drugs away”.

9 32. Also during Inspector S.M.’s visit to Respondent Tri Star on January 12, 2023, she
10 asked Respondent Tran to show her the most recent Schedule II Substance Reconciliation Report
11 (“Report”). Respondent Tran showed Inspector S.M. the Report from September 1, 2022 to
12 December 31, 2022. The Report was missing items, including the count expected and any
13 variances.

14 33. On or about January 12 and 17, 2023, Inspector S. M. received by email from
15 Respondent Tri Star its COVID vaccine invoices, and also its confirmation that for every 20 True
16 Metrix blood glucose meters it purchased from McKesson, it received 6 free meters. Respondent
17 Tri Star purchased 138 True Metrix blood glucose meters from McKesson and thus received 42
18 additional meters for free. Further review of Respondent Tri Star’s documentation revealed
19 another 10 meters purchased from other providers. This equals a purchase by Respondent Tri
20 Star of 190 blood glucose meters.

21 34. Inspector S.M. conducted an audit of the records provided by Respondents and their
22 wholesalers and suppliers regarding dangerous drugs and devices, including Respondents
23 handling of COVID home testing kits and True Metrix blood glucose meters. The acquisition
24 totals minus the disposition totals equals the variance. A negative variance shows a shortage,
25 meaning the pharmacy is missing drugs or devices. A positive variance shows an overage,
26 meaning the pharmacy dispensed more drugs or devices than it purchased.

27 35. The audit of the COVID home testing kits from January 1, 2020 to October 31, 2022
28 revealed overages of 2,405 COVID home testing kits. The overages show that Respondents

1 processed more devices than they purchased, indicative of insurance fraud, and making an
2 additional \$175,035.00 in total sales.

3 36. The audit of True Metrix blood glucose meters from January 1, 2020 to October 31,
4 2022 revealed overages of 124 True Metrix blood glucose meters. Respondent Tri Star processed
5 claims for 314 meters (but having purchased from wholesalers only 190), recording \$1,705.00 in
6 sales for dangerous devices Respondents never themselves purchased from wholesalers. The
7 overages show that Respondents processed more devices than they purchased, indicative of
8 insurance fraud.

9 **FIRST CAUSE FOR DISCIPLINE**

10 (Allowing Unlicensed Personnel to Perform Duties of a Pharmacy Technician - Against
11 Respondents Tri Star and Tran)

12 37. Respondents Tri Star and Tran are subject to disciplinary action for unprofessional
13 conduct pursuant to Code section 4301, subdivision (o), for violating laws governing the practice
14 of pharmacy, in that Respondents failed to comply with Code section 4115, subdivisions (a) and
15 (e), when they allowed unlicensed personnel to perform duties of a pharmacy technician, as set
16 forth more specifically in paragraph 31, and incorporated herein.

17 **SECOND CAUSE FOR DISCIPLINE**

18 (Allowing Unlicensed Personnel to Have Access to Pharmacy Key and Opening Pharmacy for
19 Business - Against Respondents Tri Star and Tran)

20 38. Respondents Tri Star and Tran are subject to disciplinary action for unprofessional conduct
21 pursuant to Code section 4301, subdivision (o), for violating laws and regulations governing the
22 practice of pharmacy, in that Respondents failed to comply with CCR section 1714, subdivision
23 (d), by allowing unlicensed personnel to have access to the pharmacy key and to open the
24 pharmacy, as set forth more specifically in paragraph 23, and incorporated herein.

25 ///

26 ///

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

THIRD CAUSE FOR DISCIPLINE

(Storing Prescription Documents and Wholesale Invoices in Unsecure Area - Against Respondents Tri Star and Tran)

39. Respondents Tri Star and Tran are subject to disciplinary action for unprofessional conduct pursuant to Code section 4301, subdivision (o), for violating laws and regulations governing the practice of pharmacy, in that Respondents violated CCR section 1714, subdivision (d), by storing prescription documents and wholesale invoices in an unsecure area, as set forth more specifically in paragraph 24, and incorporated herein.

FOURTH CAUSE FOR DISCIPLINE

(Failure to Maintain Pharmacy in Clean and Orderly Condition - Against Respondents Tri Star and Tran)

40. Respondents Tri Star and Tran are subject to disciplinary action for unprofessional conduct pursuant to Code section 4301, subdivision (o), for violating laws and regulations governing the practice of pharmacy, in that Respondents failed to comply with CCR section 1714, subdivision (c), by failing to maintain the pharmacy in a clean and orderly condition, as set forth more specifically in paragraph 25, and incorporated herein.

FIFTH CAUSE FOR DISCIPLINE

(Failure to Ensure Proper Storage of Medications - Against Respondents Tri Star and Tran)

41. Respondents Tri Star and Tran are subject to disciplinary action for unprofessional conduct pursuant to Code section 4301, subdivision (o), for violating laws regulating dangerous drugs, and for violating laws and regulations governing the practice of pharmacy, in that Respondents failed to comply with CCR section 1714, subdivision (b), by failing to ensure proper storage of medications in the refrigerator and freezer, as set forth more specifically in paragraph 26, and incorporated herein.

///
///
///
///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

SIXTH CAUSE FOR DISCIPLINE

(Failure to Complete Controlled Substance Reconciliation Report as Required by Law - Against Respondents Tri Star and Tran)

42. Respondents Tri Star and Tran are subject to disciplinary action for unprofessional conduct pursuant to Code section 4301, subdivisions (j) and (o), in that respondents violated laws regulating controlled substances and violated laws and regulations governing the practice of pharmacy, when Respondents failed to comply with CCR section 1715.65, by failing to complete the controlled substance reconciliation report as required by, among others, subdivisions (a), (c) and (e), as set forth more specifically in paragraphs 27 and 32, and incorporated herein.

SEVENTH CAUSE FOR DISCIPLINE

(Failure to Provide Notice of Consumer Right to Consultation and Medications Guide - Against Respondents Tri Star and Tran)

43. Respondents Tri Star and Tran are subject to disciplinary action for unprofessional conduct pursuant to Code section 4301, subdivision (o), in that Respondents violated laws and regulations governing the practice of pharmacy, by failing to comply with CCR section 1707.2, subdivision (b), by failing to provide the notice of the right to a consultation and medications guides, as set forth more specifically in paragraph 28, and incorporated herein.

EIGHTH CAUSE FOR DISCIPLINE

(Failure to Reverse Prescription Claims and Returning Medications to Shelf Within 14 Days After Processing Prescriptions Never Purchased - Against Respondents Tri Star and Tran)

44. Respondents Tri Star and Tran are subject to disciplinary action for unprofessional conduct pursuant to Code section 4301, subdivision (f), committing acts involving moral turpitude, dishonesty, fraud, deceit, or corruption, by failing to reverse the prescription claim and put the medication back on the shelf more than 14 days after processing prescription claims for drugs never purchased, as set forth more specifically in paragraph 22, and incorporated herein.

///
///
///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

NINTH CAUSE FOR DISCIPLINE

(Overages of Sales of COVID Testing Kits; Processing More Devices Than Purchased From Wholesalers - Against Respondents Tri Star and Tran)

45. Respondents Tri Star and Tran are subject to disciplinary action for unprofessional conduct pursuant to Code section 4301, subdivision (f), committing acts involving moral turpitude, dishonesty, fraud, deceit, or corruption, by making and recording overages of sales of COVID testing kits (processing more devices than purchased from wholesalers) - both evidence of insurance fraud, as set forth more specifically in paragraphs 34 and 35, and incorporated herein

TENTH CAUSE FOR DISCIPLINE

(Failure to Maintain Complete Accountability of all Dangerous Devices - Against Respondents Tri Star and Tran)

46. Respondents Tri Star and Tran are subject to disciplinary action for unprofessional conduct pursuant to Code section 4301, subdivision (o), for violating laws and regulations governing pharmacy, in that Respondents violated Code section 4081, subdivision (d), and CCR, section 1718, by failing to maintain complete accountability of all dangerous devices, as set forth more specifically in paragraphs 33 through 36, and incorporated herein.

OTHER MATTERS

47. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit number PHY 56125, issued to SacRx Corporation dba Tri Star Pharmacy 2, with Toan D. Bui Chief Executive Officer, 100% Shareholder, Director, Secretary, and Treasurer/Chief Financial Officer, then SacRx Corporation dba Tri Star Pharmacy 2 shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Pharmacy Permit number PHY 56125 is placed on probation or until Pharmacy Permit number PHY 56125 is reinstated if it is revoked.

48. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit number PHY 56125, issued to SacRx Corporation dba Tri Star Pharmacy 2, with Toan D. Bui Chief Executive Officer, 100% Shareholder, Director, Secretary, and Treasurer/Chief Financial Officer, then Toan D. Bui shall be prohibited from serving as a manager, administrator, owner, member,

1 officer, director, associate, or partner of a licensee for five years if Pharmacy Permit number PHY
2 56125 is placed on probation or until Pharmacy Permit number PHY 56125 is reinstated if it is
3 revoked.

4 49. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License
5 number RPH 56990, issued to Hanh Hong Thi Tran, then Hanh Hong Thi Tran shall be prohibited
6 from serving as a manager, administrator, owner, member, officer, director, associate, or partner
7 of a licensee for five years if Pharmacist License number RPH 56990 is placed on probation or
8 until Pharmacist License number RPH 56990 is reinstated if it is revoked.

9 **PRAYER**

10 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
11 and that following the hearing, the Board of Pharmacy issue a decision:

12 1. Revoking or suspending Pharmacy Permit number PHY 56125, issued to SacRx
13 Corporation dba Tri Star Pharmacy 2, with Toan D. Bui Chief Executive Officer, 100%
14 Shareholder, Director, Secretary, and Treasurer/Chief Financial Officer;

15 2. Revoking or suspending Pharmacist License number RPH 56990, issued to Hanh
16 Hong Thi Tran;

17 3. Prohibiting SacRx Corporation dba Tri Star Pharmacy 2 from serving as a manager,
18 administrator, owner, member, officer, director, associate, or partner of a licensee for five years if
19 Pharmacy Permit number PHY 56125 is placed on probation, or until Pharmacy Permit number
20 PHY 56125 is reinstated, if revoked;

21 4. Prohibiting Toan D. Bui from serving as a manager, administrator, owner, member,
22 officer, director, associate, or partner of a licensee for five years if Pharmacy Permit number PHY
23 56125 is placed on probation, or until Pharmacy Permit number PHY 56125 is reinstated, if
24 revoked;

25 5. Prohibiting Toan D. Bui from serving as a manager, administrator, owner, member,
26 officer, director, associate, or partner of a licensee for five years if Pharmacist License number
27 RPH 56990 is placed on probation, or until Pharmacist License number RPH 56990 is reinstated,
28 if revoked;

1 6. Ordering SacRx Corporation dba Tri Star Pharmacy 2 and Hanh Hong Thi Tran to
2 pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case,
3 pursuant to Business and Professions Code section 125.3; and,

4 7. Taking such other and further action as deemed necessary and proper.

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

DATED: 7/20/2023

Sodergren,
Anne@DCA
ANNE SODERGREN
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

 Digitally signed by Sodergren,
Anne@DCA
Date: 2023.07.20 21:51:17 -07'00'

SA2023301097
37194672.docx